Navigation Links
Researchers Identify Novel Mechanism That Make Cancer Tumors Grow
Date:2/10/2009

Scientists at the Institute for Myeloma and Bone Cancer Research (IMBCR) have uncovered a new pathway that could explain how blood vessels form within tumors.

LOS ANGELES, Feb. 10 /PRNewswire-USNewswire/ -- IMBCR researchers uncovered a new way that cancers orchestrate the production of their own blood supply. Recent studies have shown that many tumors make a protein called pleiotrophin (PTN). They now show that PTN produced by tumor cells in multiple myeloma, a common form of bone marrow-based cancer, changes white cells in the blood called "monocytes" into cells that form the lining of blood vessels called "vascular endothelial cells" (VEC). These VEC cells then become incorporated into the blood vessels that form within tumors.

"This is exciting news, and we feel this will not only have a tremendous impact on hematological tumors, such as myeloma, but other cancers as well," said James R. Berenson, M.D., Medical and Scientific Director of the IMBCR. "By uncovering this unique mechanism, how PTN produced by cancers actually changes circulating white cells into cells that line blood vessels that feed the tumor, we can direct our efforts to create more targeted approaches to eliminate blood supplies for cancers which should dramatically improve therapies for many types of cancers."

Haiming Chen, M.D., Ph.D. is the first author of the research, published this week on the cover of BLOOD. Drs. Berenson and Chen collaborated with scientists at Hemaquest, the Scripps Research Institute, Department of Molecular and Experimental Medicine and Cell Biology at Cedars-Sinai Medical Center, Departments of Neurosurgery, Pathology, and Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California at Los Angeles.

Part of IMBCR's multi-year research project, "Cure Myeloma Project," this research was funded by grants from the Skirball and Annenberg Foundations, Kramer Family Foundation and the Myeloma Research Fund.

About IMBCR

The Institute for Myeloma and Bone Cancer Research is a non-profit organization headquartered in Los Angeles, California. IMBCR is the only independent cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the blood cells that reside in the bone marrow.

IMBCR research has been published in most major oncology journals; Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Cancer, Clinical Cancer Research, Clinical Lymphoma and Myeloma, Oncogene, and the British Journal of Haematology. www.imbcr.org


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: